Google
IMVT — IMMUNOVANT INC (Healthcare >> Biotechnology)
IMVT FAQ
What is IMVT's ROE?
IMMUNOVANT INC reports a Return on Equity (ROE) of -59.30%.
What is IMVT's dividend yield?
IMMUNOVANT INC offers a dividend yield of 0.00%.
What is IMVT's Deepscope Quality Score?
Deepscope rates IMVT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IMVT?
Deepscope's AI Timing Score for IMVT is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IMVT belong to?
IMMUNOVANT INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 31.11
Price
-1.56
(-4.78%)
Day Change
|
|
|---|
IMVT, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 31.11 |
| PBV / Sector |
7.43 / 4.63
|
| Earning Per Share | -2.77 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
83.15 M
|
| Average 1W Daily Value |
47.82 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:46 |
| Symbol | IMVT |
| Name | IMMUNOVANT INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 205.31 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,337.40 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1000 Park Forty Plaza, Durham, NC, United States, 27713
Phone: 917 410 3120
Website: https://immunovant.com
Employees: 315
Sector: Healthcare >> Biotechnology
Description: Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
